English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

As the number of Alzheimer's disease (AD) prevention studies grows, many individuals will need to learn their genetic and/or biomarker risk for the disease to determine trial eligibility. An alternative to traditional models of genetic counseling and disclosure is needed to provide comprehensive standardized counseling and disclosure of apolipoprotein E ( APOE ) results efficiently, safely, and effectively in the context of AD prevention trials.    Methods  A multidisciplinary Genetic Testing, Counseling, and Disclosure Committee was established and charged with operationalizing the Alzheimer's Prevention Initiative (API) Genetic Counseling and Disclosure Process for use in the API Generation Program trials. The objective was to provide consistent information to research participants before and during the  APOE  counseling and disclosure session using standardized educational and session materials.    Results  The Genetic Testing, Counseling, and Disclosure Committee created a process consisting of eight components: requirements of  APOE  testing and reports, psychological readiness assessment, determination of AD risk estimates, guidance for identifying providers of disclosure, predisclosure education,  APOE  counseling and disclosure session materials,  APOE  counseling and disclosure session flow, and assessing  APOE  disclosure impact.    Discussion  The API Genetic Counseling and Disclosure Process provides a framework for large‐scale disclosure of  APOE  genotype results to study participants and serves as a model for disclosure of biomarker results. The process provides education to participants about the meaning and implication(s) of their  APOE  results while also incorporating a comprehensive assessment of disclosure impact. Data assessing participant safety and psychological well‐being before and after  APOE  disclosure are still being collected and will be presented in a future publication.

alzheimer's and dementia: translational research and clinical interventions

Alzheimer's Prevention Initiative Generation Program: Development of an  APOE  genetic counseling and disclosure process in the context of clinical trials